Adaptive biotechnologies stock.

Jun 2, 2023 · Wood has been adding to Adaptive Biotechnologies -- with a market cap barely above $1 billion -- in recent days. Homing in on immune-system genetic sequencing technology, Adaptive hasn't had a ... Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings …Adaptive Biotechnologies CEO on the company’s IPO and pipeline. Adaptive has agreed to spend a minimum of $12 million on Azure over seven years, according to its IPO prospectus, and Microsoft is ...The Investor Relations website contains information about Adaptive Biotechnologies's business for stockholders, potential investors, and financial analysts.

Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) ... Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2022 and December 31, 2021; 142,784,868 and 141,393,865 shares issued and outstanding at June 30, 2022 and …Adaptive Biotechnologies ( NASDAQ: ADPT) stock fell ~10% on Tuesday after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May. The Seattle-based life ...Nov 9, 2023 · SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Maneesh Tandon. Employment: Roche (I) Stock and Other Ownership Interests: Roche Pharma AG. Anna-Maria Fink. Research Funding: Celgene/Bristol Myers Squibb (Inst), AstraZeneca (Inst)

Complete Adaptive Biotechnologies Corp. stock information by Barron's. View real-time ADPT stock price and news, along with industry-best analysis. The growth-stock investor added to her stakes in UiPath (PATH 26.72%), Prime Medicine (PRME 11.02%), and Adaptive Biotechnologies (ADPT 7.31%) on Thursday. What does Wood see in these three ...According to the Biotechnology Industry Organization, there are more than 250 biotechnology products available, including medicines, vaccines, fertilizers, pest-resistant crops, bio-fuels and bio-defense products.Apr 18, 2023 · April 18, 2023 at 12:10 PM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 6.4x Adaptive Biotechnologies Corporation ( NASDAQ:ADPT) is a stock to potentially avoid ...

May 26, 2023 · The growth-stock investor added to her stakes in UiPath (PATH 26.72%), Prime Medicine (PRME 11.02%), and Adaptive Biotechnologies (ADPT 7.31%) on Thursday. What does Wood see in these three ...

Adaptive Biotechnologies Corporation (ADPT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Adaptive Biotechnologies ...

Apr 11, 2023 · Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of April 11, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.17. Adaptive Biotechnologies Corp is down 4.89% from its previous closing price of $8.59. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.33 and $8.61. Phone Number (206) 659-0067. Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection …SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...Adaptive Biotech hires Goldman Sachs to explore ‘strategic alternatives’ for key business lines With revenues declining and net losses increasing, Seattle-based Adaptive Biotechnologies on Thursday said it hired Goldman Sachs to help conduct a review of strategic alternatives for its Minimal Residual Disease (MRD) and Immune Medicine …Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%.

Some examples of biotechnology include human gene therapy, genetically modifying plants and changing the genes of bacteria. Biotechnology helps improve crops so they produce more, healthier produce. It also helps fight human diseases.Stock. Stock Quote & Chart ... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune ...Shares of Adaptive Biotechnologies ... The clinical-stage biotech company's stock closed last week at $7.31, then rose to as high as $9.08 on Wednesday. The stock is up a little more than 10% so ...Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.51% and 0.31%, ... Do the numbers hold clues to what lies ahead for the stock? Adaptive Biotechnologies ...Nov 9, 2023 · SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third ...

Nov 7, 2023 · SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ... Jim Halley Shares of Adaptive Biotechnologies (NASDAQ:ADPT) were up 15.7 ... Because of this stock market crash, some wonderful stocks are super cheap in 2022.4.3500. -0.1600. -3.55%. SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company ...Find the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Adaptive Biotechnologies ...Shares of Adaptive Biotechnologies ... The clinical-stage biotech company's stock closed last week at $7.31, then rose to as high as $9.08 on Wednesday. The stock is up a little more than 10% so ...Adaptive Biotechnologies Corp (NASDAQ:ADPT) 4.64 Delayed Data As of Nov 29 +0.27 / +6.18% Today’s Change 2.61 Today ||| 52-Week Range 10.79 -39.27% Year-to-Date Quote Profile News Charts...SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ...52 Week Low. Data Provided by Refinitiv. Minimum 15 minutes delayed. RSS Feeds.

Adaptive Biotechnologies Stock Performance. NASDAQ ADPT opened at $4.33 on Tuesday. Adaptive Biotechnologies Co. has a one year low of $2.61 and a one year high of $10.79. The company has a 50-day ...

Aug 2, 2023 · Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 7.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ADPT Earnings Date and Information. Adaptive Biotechnologies last announced its earnings data on November 9th, 2023. The reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.03. The business earned $37.92 million during the quarter, compared to analyst estimates of $43.26 million.Adaptive Biotechnologies Corp is down 9.82% from its previous closing price of $8.25. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.20 and $8.61. Currently, there are 143.06 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s P ...Historical daily share price chart and data for Adaptive Biotechnologies since 2019 adjusted for splits and dividends. The latest closing stock price for Adaptive Biotechnologies as of November 24, 2023 is 4.37.. The all-time high Adaptive Biotechnologies stock closing price was 67.74 on January 22, 2021.; The Adaptive …Future price of the stock is predicted at 0$ (-100% ) after a year according to our prediction system. This means that if you invested $100 now, your current ...View today's Adaptive Biotechnologies Corp stock price and latest ADPT news and analysis. Create real-time notifications to follow any changes in the live stock price.ADPT - Adaptive Biotechnologies Corp Stock quote - CNNMoney.com Adaptive Biotechnologies Corp (NASDAQ:ADPT) 4.64 Delayed Data As of Nov 29 +0.27 / …Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.View the latest Adaptive Biotechnologies Corp. (ADPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.Oct 4, 2023 · Adaptive Biotechnologies Corp is down 7.85% from its previous closing price of $5.22. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $5.12 and $5.30. Currently, there are 144.40 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s P ... Adaptive Biotechnologies Corporation announces a multi-year collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ® assay technology across the company’s pipeline of treatments for patients with lymphoid malignancies. This collaboration aims to support the clinical development and potential …SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended ...It should be noted that over the last three months, corporate insiders have sold a total of 248,613 shares of Adaptive Biotechnologies stock, with a cumulative value of $2,006,083. As a result, corporate insiders now hold 5.20% of the company’s stock.

Adaptive Biotechnologies reiterates full year 2022 revenue to be in the range of $185 million to $195 million. Webcast and Conference Call Information. Adaptive Biotechnologies will host a conference call to discuss its first quarter 2022 financial results after market close on Wednesday, May 4, 2022 at 4:30 PM Eastern Time.Nov 2, 2023 · Stock. Stock Quote & Chart ... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune ... With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Instagram:https://instagram. what are the most valuable us quartersrobinhood day tradetrading cryptocurrency for beginners1979 liberty one dollar coin ADPT Earnings Date and Information. Adaptive Biotechnologies last announced its earnings data on November 9th, 2023. The reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.03. The business earned $37.92 million during the quarter, compared to analyst estimates of $43.26 million. real world portalrare quarter dollar April 18, 2023 at 12:10 PM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 6.4x Adaptive Biotechnologies Corporation ( NASDAQ:ADPT) is a stock to potentially avoid ... 4 week treasury bill rate today ... shares and is commonly used to measure how much a company is worth. Market cap history of Adaptive Biotechnologies from 2019 to 2023. 2020 2021 2022 2023 $2B ...On November 9, Adaptive Biotechnologies will report earnings from Q3. Wall Street analysts predict losses per share of $0.339. Track Adaptive Biotechnologies stock price in real-time ahead here ...